Skip to main content
Monopar Therapeutics logo

Monopar Therapeutics — Investor Relations & Filings

Ticker · MNPR ISIN · US61023L2079 LEI · 549300QJFAI7L6YHKG83 US Professional, scientific and technical activities
Open in API
Filings indexed 481 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country US United States of America
Listing US MNPR

About Monopar Therapeutics

https://www.monopartx.com/

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its oncology pipeline focuses on radiopharmaceutical candidates targeting the urokinase plasminogen activator receptor (uPAR) in advanced solid tumors. These include MNPR-101-Zr for imaging, the clinical-stage therapeutic MNPR-101-Lu, and the late-preclinical stage therapeutic MNPR-101-Ac. For rare diseases, the company is advancing ALXN1840, a late-stage investigational drug for the treatment of Wilson Disease. Monopar builds its pipeline through in-house development and by in-licensing late-stage clinical assets.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 88% confidence The document is a United States SEC Form 8-K "Current Report" (a regulatory filing under the Securities Exchange Act of 1934). It does not itself contain substantive financial statements or detailed presentation content but instead furnishes as an exhibit (99.1) a presentation under Regulation FD. This is neither an earnings release nor a financial report, but a generic regulatory disclosure filing. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-29 English
FORM 8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, furnishing a Regulation FD press release. It is a regulatory compliance filing, not a financial report, earnings release, or other specialized document. Therefore, it falls under the general "Regulatory Filings" category.
2026-05-19 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
FORM 8-K
Report Publication Announcement Classification · 88% confidence The document is a Form 8-K current report (dated May 14, 2026) under Item 2.02 “Results of Operations and Financial Condition” that states a press release with first quarter financial results is attached as Exhibit 99.1. The text itself does not include the earnings highlights but merely furnishes the press release. At ~3,600 characters and noting that a report “is attached,” this is not the report itself but an announcement of its publication. Per the “Menu vs Meal” rule, this falls under Report Publication Announcement (RPA), not an Earnings Release (ER) or full financial report.
2026-05-14 English
ARS - Monopar Therapeutics (0001645469) (Filer)
Annual Report
2026-04-30 English
8-K - Monopar Therapeutics (0001645469) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 19, 2026. It reports a Regulation FD Disclosure about a press release and poster presentation related to clinical trial results presented at a medical conference. The document includes references to exhibits (press release and poster) but does not contain detailed financial statements or substantive financial data. The length is 3546 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. The content is primarily an announcement of a press release and presentation, not the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.